The Greatest Guide To P-gb-IN-1
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo targets have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis